Seeking Alpha

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum ...
Seeking Alpha

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the ...
Nasdaq

AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025

AEON Biopharma, Inc. announced in its press release that it is advancing its biosimilar development program for ABP-450, a botulinum toxin complex, by initiating analytical studies to prepare for a ...
Nasdaq

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

--AEON Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has ...